797 related articles for article (PubMed ID: 17505020)
1. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
[TBL] [Abstract][Full Text] [Related]
3. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
4. Detection of Aβ plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice.
Li S; He H; Cui W; Gu B; Li J; Qi Z; Zhou G; Liang CM; Feng XY
Anat Rec (Hoboken); 2010 Dec; 293(12):2136-43. PubMed ID: 21089051
[TBL] [Abstract][Full Text] [Related]
5. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.
Lee HJ; Zhang Y; Zhu C; Duff K; Pardridge WM
J Cereb Blood Flow Metab; 2002 Feb; 22(2):223-31. PubMed ID: 11823720
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
7. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway.
Jaffar S; Counts SE; Ma SY; Dadko E; Gordon MN; Morgan D; Mufson EJ
Exp Neurol; 2001 Aug; 170(2):227-43. PubMed ID: 11476589
[TBL] [Abstract][Full Text] [Related]
8. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.
Poduslo JF; Curran GL; Peterson JA; McCormick DJ; Fauq AH; Khan MA; Wengenack TM
Biochemistry; 2004 May; 43(20):6064-75. PubMed ID: 15147190
[TBL] [Abstract][Full Text] [Related]
9. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.
El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M
Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798
[TBL] [Abstract][Full Text] [Related]
10. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.
Pihlaja R; Koistinaho J; Malm T; Sikkilä H; Vainio S; Koistinaho M
Glia; 2008 Jan; 56(2):154-63. PubMed ID: 18004725
[TBL] [Abstract][Full Text] [Related]
11. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.
Kurt MA; Davies DC; Kidd M; Duff K; Rolph SC; Jennings KH; Howlett DR
Exp Neurol; 2001 Sep; 171(1):59-71. PubMed ID: 11520121
[TBL] [Abstract][Full Text] [Related]
12. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice.
Dhenain M; El Tannir El Tayara N; Wu TD; Guégan M; Volk A; Quintana C; Delatour B
Neurobiol Aging; 2009 Jan; 30(1):41-53. PubMed ID: 17588710
[TBL] [Abstract][Full Text] [Related]
13. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice.
Kulnane LS; Lamb BT
Neurobiol Dis; 2001 Dec; 8(6):982-92. PubMed ID: 11741394
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP.
Li L; Zhang X; Yang D; Luo G; Chen S; Le W
Neurobiol Aging; 2009 Jul; 30(7):1091-8. PubMed ID: 18063223
[TBL] [Abstract][Full Text] [Related]
15. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
16. Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS.
Woo DC; Lee SH; Lee DW; Kim SY; Kim GY; Rhim HS; Choi CB; Kim HY; Lee CU; Choe BY
Behav Brain Res; 2010 Jul; 211(1):125-31. PubMed ID: 20307581
[TBL] [Abstract][Full Text] [Related]
17. Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain.
Zhang LH; Wang X; Zheng ZH; Ren H; Stoltenberg M; Danscher G; Huang L; Rong M; Wang ZY
Neurobiol Aging; 2010 Jan; 31(1):74-87. PubMed ID: 18378045
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging.
Braakman N; Matysik J; van Duinen SG; Verbeek F; Schliebs R; de Groot HJ; Alia A
J Magn Reson Imaging; 2006 Sep; 24(3):530-6. PubMed ID: 16892201
[TBL] [Abstract][Full Text] [Related]
19. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes.
Howlett DR; Richardson JC; Austin A; Parsons AA; Bate ST; Davies DC; Gonzalez MI
Brain Res; 2004 Aug; 1017(1-2):130-6. PubMed ID: 15261108
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
